Clinical Trials Logo

Mild Cognitive Impairment clinical trials

View clinical trials related to Mild Cognitive Impairment.

Filter by:

NCT ID: NCT03911765 Recruiting - Aging Clinical Trials

Effect of Digital Cognitive Training on the Functionality of Older Adults With Mild Cognitive Impairment (MCI)

Start date: January 2, 2019
Phase: Phase 1
Study type: Interventional

The purpose of this study is to investigate the effect of digital cognitive training in the functionality of older adults with Mild Cognitive Impairment.

NCT ID: NCT03906903 Recruiting - Clinical trials for Mild Cognitive Impairment

Transcranial Magnetic Stimulation and Cognitive Stimulation in Mild Cognitive Impairment

rTMS&MCI
Start date: March 5, 2018
Phase: N/A
Study type: Interventional

This study evaluates the effect of 5Hertz (Hz) repetitive Transcranial Magnetic Stimulation (rTMS) on Left Dorsolateral Prefrontal Cortex enhancing Cognitive Stimulation in Mild Cognitive Impairment.

NCT ID: NCT03903211 Completed - Alzheimer Disease Clinical Trials

Longitudinal Changes of [18F]PI-2620 Positron Emission Tomography in Subjects With Cognitively Normal, Mild Cognitive Impairment and Alzheimer's Disease

Start date: April 9, 2019
Phase: Phase 2
Study type: Interventional

The overall goal of this imaging trial is to evaluate crosssectional difference and longitudinal changes of [18F]PI-2620, a tau targeted positron emission computed tomography radioligand, in cognitively normal individuals, and subjects with mild cognitive impairment and Alzheimer's disease.

NCT ID: NCT03896308 Recruiting - Clinical trials for Mild Cognitive Impairment

Reliability of Chinese Version of Verbal Learning Test and Selective Reminding Test

Start date: May 25, 2019
Phase:
Study type: Observational [Patient Registry]

Mild cognitive impairment (MCI) is distinguished from healthy aging by cognitive difficulties that are greater than expected for one's age and education. Amnestic mild cognitive impairment (aMCI) is a major sub-type of MCI with noticeable impairments in memory. Approximately 12% of aMCI will progress to AD per year. There are two test to evaluate the effects on memory, but both without Chinese version. This study is to know the test-retest reliability of the Chinese version of the Verbal learning test and Selective reminding test among people with mild cognitive impairment.

NCT ID: NCT03895346 Completed - Aging Clinical Trials

Mental Training for Adults With Mild Cognitive Impairment

Start date: April 10, 2019
Phase: N/A
Study type: Interventional

This study aims to determine the feasibility and acceptability of conducting a larger randomized clinical trial to test whether individuals with MCI can benefit from mental training programs.

NCT ID: NCT03887741 Enrolling by invitation - Clinical trials for Mild Cognitive Impairment

Plasmapheresis Versus Plasma Infusion From Young APOE3 Homozygotes Into MCI APOE4 Homozygotes to Slow Disease Progression

Start date: September 15, 2021
Phase: Phase 1
Study type: Interventional

Determine safety of plasma infusion or exchange in APOE 44 patients.

NCT ID: NCT03883633 Completed - Alzheimer Disease Clinical Trials

Reversal of Cognitive Decline (ReCODE) Study

RECODE
Start date: June 30, 2019
Phase:
Study type: Observational

Prospective study on patients enrolled in the ReCODE treatment protocol

NCT ID: NCT03883308 Completed - Clinical trials for Mild Cognitive Impairment

The Influence of Multi-domain Cognitive Training on Large-scale Structural and Functional Brain Networks in MCI

Start date: October 30, 2017
Phase: N/A
Study type: Interventional

The purpose of this study is to integrate advanced computational techniques and multimodal neuroimaging methods to examine the potential effects of long-term, multi-domain, online, computerized cognitive training on large-scale structural and functional brain networks in older adults with mild cognitive impairment (MCI).

NCT ID: NCT03881579 Active, not recruiting - Dementia Clinical Trials

Supportive Care for Cognitively Impaired Patients and Families

Start date: December 18, 2019
Phase: N/A
Study type: Interventional

Currently almost 5 million Americans suffer from the distressing symptoms related to dementia and this number that will triple by 2050. The overall goals of the proposed project are to evaluate, in community dwelling Alzheimer's Disease Research Center participants the benefits of a 12-month nurse-led early palliative intervention on symptoms, quality of life, health care resource use. The relevance of this research to public health is that there is an urgent need to improve the palliative care of persons with dementia living in the community. This study will contribute substantially to that effort.

NCT ID: NCT03880240 Recruiting - Alzheimer Disease Clinical Trials

Gamma Induction for Alzheimer's Disease

Start date: August 5, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

Alzheimer's Disease (AD) is characterized by amyloid-β (Aβ) plaque buildup and phosphorylated tau (p-tau) in the brain, as well as widespread neurodegeneration. Amyloid-β and tau are proteins that build up in the brain that may contribute to memory problems. The evidence suggests that both amyloid and tau play a critical role in AD and interventions that reliably and safely decrease the intracerebral burden of amyloid or tau could potentially be of marked clinical importance. Currently, therapeutic options are very limited and while there are pharmacologic interventions that transiently improve cognitive function, there are no treatments that alter disease progression. The purpose of this study is to see if multiple daily sessions of non-invasive brain stimulation can affect brain activity to decrease the amount of amyloid and tau in people with AD as compared to Sham (placebo) stimulation. The type of brain stimulation that will be used is called transcranial alternating current stimulation (tACS). This study will investigate different doses of tACS (2-4 weeks) and assess safety. The hope is that tACS will decrease the amount of amyloid and tau and improve memory and thinking in people with AD.